Advanced science, 2019. 6(11), 1802115-, DOI: https://doi.org/10.1002/advs.201802115

A Novel Blood-Based Colorectal Cancer Diagnostic Technology Using Electrical Detection of Colon Cancer Secreted Protein-2

Minhong Jeun, Hyo Jeong Lee;Sungwook Park;Eun-ju Do;Jaewon Choi;You-Na Sung;Seung-Mo Hong;Sang-Yeob Kim;Dong-Hee Kim;Ja Young Kang;Hye-Nam Son;Jinmyoung Joo;Eun Mi Song;Sung Wook Hwang;Sang Hyoung Park;Dong-Hoon Yang;Byong Duk Ye;Jeong-Sik Byeon;Jaewon Choe;Suk-Kyun Yang;Helen Moinova;Sanford D. Markowitz;Kwan Hyi Lee;Seung-Jae Myung

Abstract

Colorectal cancer (CRC) is the second-leading cause of cancer-related mortalityworldwide, which may be effectively reduced by early screening. Colon cancersecreted protein-2 (CCSP-2) is a promising blood marker for CRC. An electricfieldeffect colorectal sensor (E-FECS), an ion-sensitive field-effect transistorunder dual gate operation with nanostructure is developed, to quantify CCSP-2directly from patient blood samples. The sensing performance of the E-FECSis verified in 7 controls and 7 CRC samples, and it is clinically validated on30 controls, 30 advanced adenomas, and 81 CRC cases. The concentrationof CCSP-2 is significantly higher in plasma samples from CRC and advancedadenoma compared with controls (both P < 0.001). Sensitivity and specificityfor CRC versus controls are 44.4% and 86.7%, respectively (AUC of 0.67), and43.3% and 86.7%, respectively, for advanced adenomas (AUC of 0.67). CCSP-2detects a greater number of CRC cases than carcinoembryonic antigen does(45.6% vs 24.1%), and the combination of the two markers detects an evengreater number of cases (53.2%). The E-FECS system successfully detectsCCSP-2 in a wide range of samples including early stage cancers and advancedadenoma. CCSP-2 has potential for use as a blood-based biomarker for CRC.

• DOI: https://doi.org/10.1002/advs.201802115
• ISBN or ISSN: 2198-3844

• 본 연구는 질병관리본부 연구개발과제연구비를 지원받아 수행되었습니다.
• This research was supported by a fund by Research of Korea Centers for Disease Control and Prevention.